Working… Menu

Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00804622
Recruitment Status : Completed
First Posted : December 9, 2008
Last Update Posted : July 11, 2012
Novartis Pharmaceuticals
Information provided by:
The University of Hong Kong

Brief Summary:
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg once daily (QD) taken together versus tenofovir DF 300 mg once daily (QD) or versus telbivudine 600 mg monotherapy daily (QD). This is an open-labeled, active controlled, viral kinetics study which means the subjects and study doctor will know what study drug subjects have been assigned. This study is open to male and female subjects, <40 years of age, who have been infected with HBV for at least 6 months and have not received oral treatment for HBV.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Drug: telbivudine Drug: tenofovir disproxil fumarate Drug: telbivudine plus tenofovir disproxil fumarate Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB
Study Start Date : December 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : March 2010

Arm Intervention/treatment
Active Comparator: 1
tenofovir disproxil fumarate 300 mg monotherapy
Drug: tenofovir disproxil fumarate
daily oral administration,300mg,over 12 weeks

Active Comparator: 2
telbivudine 600 mg monotherapy
Drug: telbivudine
daily oral administration,600mg,over 12 weeks

Active Comparator: 3
telbivudine 600 mg and tenofovir disproxil fumarate 300 mg
Drug: telbivudine plus tenofovir disproxil fumarate
daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks

Primary Outcome Measures :
  1. The primary variable is the reduction of HBV DNA level over 12 weeks of treatment [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Reduction in HBV DNA level [ Time Frame: from baseline to Weeks 2, 4 and 8 ]
  2. Characterization of very early viral kinetics through estimation of various parameters [ Time Frame: week 12 ]
  3. % patients who are PCR negative [ Time Frame: Week 12 ]
  4. % of patients who achieve HBeAg loss and HBeAg seroconversion [ Time Frame: Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must meet all of the following inclusion criteria at screening to be eligible for participation in this study.

  1. Chronic HBV infection, defined as positive serum HBsAg for at least 6 months, or HBsAg positive > 3 months and negative for IgM anti-HBc and positive for IgG anti-HBc
  2. Age < 40 years old
  3. HBeAg positive
  4. HBV DNA ≥ 10^7 copies/mL by Abbott real-time PCR
  5. ALT ≤ 1 ULN
  6. Willing and able to provide written informed consent
  7. Negative serum β-HCG (for females of childbearing potential only)
  8. Calculated creatinine clearance ≥ 70 mL/min by the following formula: (140 - age in years) x (body weight [kg]) / (72) x (serum creatinine [mg/dl]) [Note: multiply estimated rate by 0.85 for women]
  9. Hemoglobin ≥ 10 g/dL
  10. Neutrophils ≥ 1,500 /mm^3
  11. No prior oral HBV therapy (e.g., nucleotide and/or nucleoside therapy or other investigational agents for HBV infection)
  12. Is willing and able to comply with the study drug regimen and all other study procedures and requirements
  13. Is willing and able to provide written informed consent before any study assessment is perform.

Exclusion Criteria:

Patients will be excluded from the study for any of the criteria:

  1. Decompensated liver disease defined as direct (conjugated) bilirubin > 1.2 × ULN, PT > 1.2 × ULN, platelets < 150,000/mm3, serum albumin < 3.5 g/dL, or prior history of clinical hepatic decompensation (e.g. ascites, jaundice, encephalopathy, variceal hemorrhage).
  2. Received interferon (pegylated or not) therapy within 6 months of the screening visit
  3. α-fetoprotein > 50 ng/mL
  4. Evidence of hepatocellular carcinoma (HCC)
  5. Co-infection with HCV (by serology), HIV, or HDV.
  6. Significant renal, cardiovascular, pulmonary, or neurological disease.
  7. Received solid organ or bone marrow transplantation.
  8. Is currently receiving therapy with immunomodulators (e.g., corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion.
  9. Has proximal tubulopathy.
  10. Use of other investigational drugs at the time of enrollment, or within 30 days
  11. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
  12. Is pregnant or breastfeeding. Women of childbearing potential must have a negative serum β - HCG during Screening.
  13. Is a women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap).
  14. Patient has any other concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study.
  15. Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years. Please refer to Appendix 3.
  16. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir. Please refer to Appendix 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00804622

Layout table for location information
Department of Medicine, Queen Mary Hospital
Hong Kong, China
Sponsors and Collaborators
The University of Hong Kong
Novartis Pharmaceuticals
Layout table for investigator information
Principal Investigator: George Lau, MD Department of Medicine, The University of Hong Kong
Layout table for additonal information
Responsible Party: Prof. George Lau, Department of Medicine, The University of Hong Kong Identifier: NCT00804622    
Other Study ID Numbers: CLDT600AHK01
First Posted: December 9, 2008    Key Record Dates
Last Update Posted: July 11, 2012
Last Verified: July 2012
Keywords provided by The University of Hong Kong:
HBeAg positive compensated chronic hepatitis B
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents